Skip to main content
. Author manuscript; available in PMC: 2017 May 11.
Published in final edited form as: Cancer Res. 2016 Mar 28;76(8):2301–2313. doi: 10.1158/0008-5472.CAN-15-0728

Figure 4.

Figure 4

Duplet and triplet combination is efficacious in human-derived xenografts. A, relative tumor growth of PDX191 following vehicle, BYL719 (35 mg/kg, once daily, 6IW), LEE011 (75 mg/kg, once daily, 6IW), or the combination (**, P < 0.01;***, P < 0.001, two-way ANOVA). The total number of tumors in each arm (n) and SEM of each point are indicated. B, Western blots with the indicated antibodies in PDX191 after 42 days of vehicle, BYL719, LEE011, or the combination. Each lane belongs to one individual tumor. C, relative tumor growth of PDX244 following vehicle, fulvestrant (5 mg/kg, i.p., 1IW), fulvestrant plus BYL719, fulvestrant plus LEE011, and fulvestrant plus BYL719 plus LEE011 treatment.